Half-year Report

Rothschild & Co Continuation Fin
18 July 2024
 

Rothschild & Co Continuation Finance PLC

Half-yearly Report for the six-month period ended 30 June 2024

 

Interim Management Report

 

Summary of Important Events

 

Rothschild & Co Continuation Finance PLC (the "Company") is a wholly-owned subsidiary of N. M. Rothschild & Sons Limited ("NMR") and was incorporated on 30 August 2000 to operate as a finance vehicle for the benefit of NMR and its subsidiaries. 

 

The principal activity of the Company is the raising of finance for the purpose of lending it to NMR and other companies in NMR's group (the "Group"). The Company raises finance by the issue of perpetual subordinated notes guaranteed by NMR. 

 

Risks and Uncertainties

 

The principal risks of the Company are credit risk, liquidity risk and market risk. The Company follows the risk management policies of the parent undertaking, NMR.  

 

The Company's principal risk is credit exposure to NMR, as the notes issued by the Company have been guaranteed by, and funds have been on-lent to NMR. The Company is therefore reliant on the ability of NMR to meet its obligations under these lending arrangements. NMR is exposed to current market and geopolitical headwinds but, nevertheless, has sufficient liquidity to continue to operate for the next 12 months even in the scenario where revenue is significantly reduced. Management has considered the going concern basis of preparation as outlined in note 1 to the financial statements.

 

This half-yearly financial report has not been audited or reviewed by the Company's auditors pursuant to the Auditing Practices Board guidance on Review of Interim Financial Information. 

 

Responsibilities Statement

 

The Directors confirm that to the best of their knowledge:

 

-     

The condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting; and

 

-     

The interim management report includes a fair review of (i) the important events that have occurred during the first six months of the financial year, and their impact on the condensed set of financial statements, and (ii) the principal risks and uncertainties for the remaining six months of the financial year. 

 

By Order of the Board

 

Peter Barbour

Director

18/07/2024

 

Condensed Interim Statement of Comprehensive Income

For the six months ended 30 June 2024

 



6 months to

6 months to



30 June
2024

30 June
2023


Note

£

£

Interest income


2,128,839

2,053,754

Interest expense


(2,128,773)

(2,042,487)

Operating profit

 

66

11,267

Revaluation of loans

4

8,007,360

(3,476,570)

Revaluation of debt securities

9

(8,011,889)

3,470,275

Foreign exchange translation (losses)/gains


9,098

(7,337)

Profit/(loss) before tax

 

4,635

(2,365)

Taxation

3

(27)

(4,084)

Profit/(loss) for the financial period

 

4,608

(6,449)

Other comprehensive income


-

-

Total comprehensive income/(loss) for the financial period

 

4,608

(6,449)

 

 

Condensed Interim Statement of Changes in Equity

For the six months ended 30 June 2024

 


 

Share Capital

Retained Earnings

Total shareholders' equity


£

£

£

At 1 January 2024

100,000

317,636

417,636

Total comprehensive income for the period

-

4,608

4,608

At 30 June 2024

100,000

322,244

422,244





At 1 January 2023

100,000

324,190

424,190

Total comprehensive loss for the period

-

(6,449)

(6,449)

At 30 June 2023

100,000

317,741

417,741

 

Condensed Interim Balance Sheet

At 30 June 2024

 



At 30 June

At 31 December



2024

2024

2023

2023


Note

£

£

£

£

Non-current assets






Loan to parent undertaking

4


97,284,560


89,277,200

Current assets






Other financial assets

5

721,582


713,960


Cash and cash equivalents

6

267,050


268,360


 

 

988,632

 

982,320


Current liabilities






Current tax liability


(1,448)


(1,904)


Deferred tax liability

7

(46,327)


(45,844)


Other financial liabilities

8

(709,155)


(712,007)


Net current assets

 

 

231,702

 

222,565

Total assets less current liabilities

97,516,262


89,499,765

Non-current liabilities






Debt securities in issue

9


(97,094,018)


(89,082,129)

Net assets

 

 

422,244

 

417,636

Shareholders' equity






Share capital

11


100,000


100,000

Retained earnings



322,244


317,636

Total shareholders' equity

 

 

422,244


417,636

 

 

Condensed Interim Cash Flow Statement

For the six months ended 30 June 2024


6 months to

6 months to



30 June
2024

30 June
2023


Note

£

£

Cash flow from operating activities




Net profit/(loss) for the financial period


4,608

(6,449)

Taxation


27

4,084

Net cash inflow/(outflow) from operating activities


4,635

(2,365)

 

Cash flow from financing activities

Net increase/(decrease) in loans and interest receivable


 

 

(8,014,982)

 

 

3,473,234

Net increase/(decrease) in debt securities in issue and interest payable


 

8,009,037

 

(3,466,913)

Net cash (outflow)/inflow from financing activities


(5,945)

6,321

 

Net (decrease)/increase in cash and cash equivalents

 

 

(1,310)

 

3,956

Cash and cash equivalents at beginning of half-year


268,360

265,057

Cash and cash equivalents at end of half-year

6

267,050

269,013

 

Interest receipts and payments during the period were as follows:

 


6 months to

6 months to


30 June 2024

30 June 2023


£

£

Interest received from parent undertaking

2,121,217

2,050,418

Interest paid to note holders

2,131,625

2,039,125

 

The Notes to the Condensed Interim Financial Statements form an integral part of the Condensed Interim Financial Statements.

 

 

Notes to the Condensed Interim Financial Statements

(forming part of the Condensed Interim Financial Statements)

For the six months ended 30 June 2024

 

1.   Basis of Preparation

 

The Condensed Interim Financial Statements are prepared and approved by the Directors in accordance with IAS 34 Interim Financial Reporting. The Condensed Interim Financial Statements are prepared under the historical cost accounting rules and should be read in conjunction with the annual financial statements for the year ended 31 December 2023, which have been prepared in accordance with International Financial Reporting Standards. 

 

The accounting policies and methods of valuation are identical to those applied in the financial statements for the year ended 31 December 2023.

 

Going Concern

Management has performed an assessment to determine whether there are any material uncertainties that could cast significant doubt on the ability of the Company to continue as a going concern. No significant issues have been noted. In reaching this conclusion, management considered:

 

-     

The financial impact of the uncertainty on the Company's balance sheet;

 

-     

The Company's liquidity position based on current and projected cash resources. The liquidity position has been assessed taking into account the forecast liquidity of NMR and its ability to continue to pay the interest on the intercompany loan provided by the Company.

 

Based on the above assessment of the Company's financial position, the Directors have concluded that the Company has adequate resources to continue in operational existence for the foreseeable future (for a period of at least twelve months after the date that the financial statements are signed). Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

 

Financial Risk Management

The Company follows the financial risk management policies of the parent undertaking, NMR.  The key risks arising from the Company's activities involving financial instruments, which are monitored at the Group level, are as follows:

 

-     

Credit risk - the risk of loss arising from client or counterparty default is not considered a significant risk to the Company as all asset balances are with other group companies as detailed in Note 12 Related Party Transactions. 

 

-     

Market risk - exposure to changes in market variables such as interest rates, currency exchange rates, equity and debt prices is not considered significant as the terms of financial assets substantially match those of financial liabilities. 

 

-     

Liquidity risk - the risk that the Company is unable to meet its obligations as they fall due or that it is unable to fund its commitments is not considered significant as the risk has been transferred to NMR.  As the funds on-lent to NMR have the same maturity dates as the notes issued, the Company's ability to meet its obligations in respect of notes issued by it is affected by NMR's ability to make payments to the Company.

 

2.   Directors' Emoluments

 

None of the directors received any remuneration in respect of their services to the Company during the period (2023: £nil). 

 

3.   Taxation

 


6 months to
30 June 2024

6 months to

30 June 2023


£

£

Current tax

(1,159)

520

Deferred tax

1,132

(4,604)

Total tax

(27)

(4,084)

 

The tax charge can be explained as follows:


6 months to

6 months to


30 June 2024

30 June 2023


£

£

Profit/(loss) before tax

4,635

(2,365)

United Kingdom corporation tax credit/(charge) at effective rate 25%

(1,159)

520

Deferred tax income statement charge

1,132

(4,604)

Tax charged for the period

(27)

(4,084)

 

 

4.   Non-Current Assets: Loan to Parent Undertaking

 


At 30 June

At 31 December


2024

2023


£

£

At beginning of period

89,277,200

92,848,908

Fair value movements

8,007,360

(3,571,708)

At end of period

97,284,560

89,277,200

Due

 

 

In 5 years or more

97,284,560

89,277,200

 

IFRS 9 requires the €150,000,000 loan to be carried at fair value which as at 30 June 2024 was £97,284,560 (at 31 December 2023: £89,277,200). On an amortised cost basis, the value of the loan at 30 June 2024 would be £127,028,217 (at 31 December 2023: £130,046,904). The fair values are based on the market value of the external debt securities (level 2).

 

The interest rate charged on the €150 million loan is EUR-TEC10-CNO plus 36 basis points, capped at 9.01% fixed on 05 February, 05 May, 05 August and 05 November each year. The interest rate on the above loan at 30 June 2024 was 3.41% (31 December 2023: 3.66%).

 

 

5.   Current Assets: Other Financial Assets

 


At 30 June

At 31 December


2024

2023


£

£

Interest receivable

721,582

713,960

 

 

6.   Cash and Cash Equivalents

 

At 30 June 2024 the Company held cash of £267,050 (31 December 2023: £268,360) at the parent undertaking.

 

7.   Deferred Income Taxes


At 30 June

At 31 December


2024

2023


£

£

At beginning of period

(45,844)

(37,915)

Recognised in income:

Income statement charge

 

(483)

(7,929)

At end of period

(46,327)

(45,844)

 

Deferred tax assets less liabilities are attributable to the following items:


At 30 June 2024

At 31 December 2023


£

£

Fair value of intra group loans

7,435,914

9,580,879

Fair value of debt securities in issue

(7,482,241)

(9,626,723)

 

(46,327)

(45,844)


Both the intra-group loans and debt securities in issue are taxed on an amortised cost basis of accounting and accordingly taxable/deductible temporary differences arise following the adoption of IFRS 9.

8.   Current Liabilities: Other Financial Liabilities

 


At 30 June

At 31 December


2024

2023


£

£

Interest payable

709,155

712,007

 

9.   Non-Current Liabilities: Debt Securities in Issue

 


At 30 June

At 31 December


2024

2023


£

£

At beginning of period

89,082,129

92,649,367

Fair value movements

8,011,889

(3,567,238)

At end of period

97,094,018

89,082,129

Due

 


In 5 years or more

97,094,018

89,082,129

 

Given the IFRS 9 requirement to fair value the related loans, the Company has elected to fair value the debt securities in issue, which as at 30 June 2024 was £97,094,018 (at 31 December 2023: £89,082,129). On an amortised cost basis, the value of the debt securities in issue at 30 June 2024 would be £127,028,217 (at 31 December 2023: £130,046,904). Consistent with the prior period, the fair value was derived from quoted market prices at the balance sheet date. In accordance with IFRS 13 and due to a reduction in the frequency and volume of transactions observed in the immediate run up to the period end, the fair value is considered to be level 2 as at 30 June 2024 (2023: level 2).

 

The interest rate payable on the €150 million Perpetual Subordinated Notes is EUR-TEC10-CNO plus 35 basis points, capped at 9 per cent, fixed on 05 February, 05 May, 05 August and 05 November each year. From and including the interest payment date falling in August 2016 and every interest payment date thereafter, the Company may redeem all (i.e. not in part) of the Perpetual Subordinated Notes at their principal amount. 

 

The interest rate on the above notes at 30 June 2024 was 3.40% (31 December 2023: 3.65%).

 

10. Maturity of Financial Liabilities

 

The following table shows contractual cash flows payable by the Company on the perpetual subordinated notes classified by remaining contractual maturity at the balance sheet date. Interest cash flows on perpetual subordinated notes are shown up to five years only, with the principal balance being shown in the perpetual column.

 

At 30 June 2024



3 months







or less

1 year

5 years





but not

or less

or less





payable on

but over

but over




Demand

demand

3 months

1 year

Perpetual

Total


£

£

£

£

£

£

Perpetual subordinated notes

 

-

 

1,079,740

 

3,239,220

 

17,275,838

 

127,028,217

 

148,623,015

 

At 31 December 2023



3 months







or less

1 year

5 years





but not

or less

or less





payable on

but over

but over




Demand

demand

3 months

1 year

Perpetual

Total


£

£

£

£

£

£

Perpetual subordinated notes

-

1,186,678

3,560,034

18,986,848

130,046,904

153,780,464

 

11.   Share Capital

 


At 30 June

At 31 December


2024

2023


£

£

Authorised, allotted, called up and fully paid



100,000 Ordinary shares of £1 each

100,000

100,000

 

12.   Related Party Transactions

 

Parties are considered to be related if one party controls, is controlled by or has the ability to exercise significant influence over the other party. This includes key management personnel, the parent company, subsidiaries and fellow subsidiaries. 

 

Amounts receivable from related parties at the period end were as follows:


At 30 June

At 31 December


2024

2023


£

£

Cash and cash equivalents at parent undertaking

267,050

268,360

Accrued interest receivable from parent undertaking

721,582

713,960

Loans to parent undertaking

97,284,560

89,277,200

 

 

Amounts recognised in the condensed statement of comprehensive income in respect of related party transactions were as follows:

 


6 months to

6 months to


30 June 2024

30 June 2023


£

£

Interest income from parent undertaking

2,128,839

2,053,754

 

There were no loans made to Directors during the period (6 months to 30 June 2023: none) and no balances outstanding at the period end (at 31 December 2023: £nil). There were no employees of the Company during the period (6 months to 30 June 2023: none).

 

13.    Parent Undertaking and Ultimate Holding Company and Registered Office

 

The largest group in which the results of the Company are consolidated is that headed by Rothschild & Co Concordia SAS, incorporated in France, and whose registered office is at 23bis, Avenue de Messine, 75008 Paris.  The smallest group in which they are consolidated is that headed by Rothschild & Co SCA, a French public limited partnership whose registered office is also at 23bis, Avenue de Messine, 75008 Paris. The accounts are available on the Rothschild & Co website at www.rothschildandco.com.

 

The Company's immediate parent company is N. M. Rothschild and Sons Limited, incorporated in England and Wales and whose registered office is at New Court, St Swithins Lane, London, EC7N 8AL. 

 

The Company's registered office is located at New Court, St Swithin's Lane, London, EC4N 8AL. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings